Rinary T News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The FDA has approved extended-release injection buprenorphine (Brixadi, Braeburn Inc) for the treatment of moderate to severe opioid use disorder.

Robertm califfMental health services administrationBraeburn incDrug administrationOverdose prevention frameworkSubstance abuseRisk evaluationMitigation strategyAdverse effectsSide effectsUs food and drug administrationNited states food and drug administrationRisk evaluation and mitigation strategies remsPatient safetyPain managementPain management